Top 10 Companies in the (R)-N-Benzyl-1-phenyl ethylamine (CAS 38235-77-7) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-N-Benzyl-1-phenyl ethylamine (CAS 38235-77-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.5% during the forecast period.

(R)-N-Benzyl-1-phenyl ethylamine is a chiral amine compound widely recognized for its role as a key building block and resolving agent in asymmetric synthesis. Characterized by its high enantiomeric purity, this compound finds application across pharmaceutical manufacturing, fine chemical synthesis, and academic research, particularly in the production of optically active intermediates essential for drug development.

The market is gaining steady momentum, driven primarily by the expanding demand for chiral intermediates within the global pharmaceutical industry, where enantioselective synthesis has become a regulatory and efficacy priority. Furthermore, the growing focus on green chemistry and efficient chiral resolution techniques continues to support adoption of high‑purity amine building blocks such as (R)-N-Benzyl-1-phenyl ethylamine. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar, each maintaining robust catalogues catering to research and industrial‑scale requirements.

(R)-N-Benzyl-1-phenyl ethylamine (CAS 38235-77-7) Market – View in Detailed Research Report

Market size for 2025 is USD 28.4 million, with an estimated rise to USD 30.1 million in 2026, and a forecasted peak of USD 52.7 million by 2034, reflecting a steady upward trajectory as demand for enantiomerically pure intermediates grows.

In addition to pharmaceutical manufacturing, the compound is leveraged in fine chemical synthesis and academic research, where its high enantiomeric excess (often >99%) enables precise control over stereochemistry in complex molecule construction.

Top 10 Companies in the (R)-N-Benzyl-1-phenyl ethylamine Market (2026)

1. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Pharmaceutical‑grade chiral amines, custom synthesis services

Tokyo Chemical Industry has positioned itself as a trusted partner for contract manufacturers, offering a portfolio of high‑purity intermediates that meet stringent regulatory requirements. Its integrated R&D and production facilities enable rapid scale‑up and support for late‑stage synthesis.

Sustainability/Growth Initiatives:

• Investment in continuous‑flow processes to enhance yield and reduce waste
• Partnerships with academic institutions to explore new asymmetric catalysts
• Commitment to carbon‑neutral production by 2035

2. Biosynth Carbosynth (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: REACH‑compliant chiral building blocks, small‑batch custom synthesis

Biosynth’s expertise in biocatalytic routes allows the company to deliver enantiomerically pure compounds with minimal environmental impact, appealing to European CDMOs seeking green solutions.

Sustainability/Growth Initiatives:

• Development of enzyme‑based synthesis pathways to lower solvent use
• Expansion of its online platform for rapid order processing
• Collaborations with biotech firms to supply chiral intermediates for biologics

3. Enamine Ltd. (Ukraine)

Headquarters: Kharkiv, Ukraine
Key Offering: Research‑grade chiral amines, rapid‑turnaround custom synthesis

Enamine’s flexible manufacturing model supports academic and industrial clients with on‑demand production, enabling swift incorporation of new chiral intermediates into research pipelines.

Sustainability/Growth Initiatives:

• Implementation of green chemistry protocols across all production lines
• Investment in renewable energy for manufacturing facilities
• Active participation in regional industry forums to shape regulatory standards

4. Finetech Industry Limited

Headquarters: Shanghai, China
Key Offering: Large‑scale pharmaceutical‑grade chiral amines, supply chain optimization

Finetech’s production capacity supports major CDMOs in Asia‑Pacific, and its focus on process intensification drives cost efficiencies for high‑volume orders.

Sustainability/Growth Initiatives:

• Adoption of solvent‑free synthetic routes
• Strategic partnerships with local universities to advance asymmetric catalysis
• Deployment of IoT monitoring for real‑time quality assurance

5. Capot Chemical Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: Technical‑grade chiral amines, rapid prototyping services

Capot’s modular production units enable quick turnaround for niche applications, making it a preferred supplier for niche pharma projects.

Sustainability/Growth Initiatives:

• Investment in renewable feedstocks for amine synthesis
• Collaboration with logistics partners to reduce carbon footprint of distribution
• Development of a digital platform for client‑centric order management

6. Wuhan Kemi‑Works Chemical Co., Ltd.

Headquarters: Wuhan, China
Key Offering: Technical‑grade chiral amines, scalable production

Wuhan Kemi‑Works leverages its extensive chemical infrastructure to deliver consistent quality across large batches, supporting both domestic and export markets.

Sustainability/Growth Initiatives:

• Implementation of closed‑loop water recycling systems
• Adoption of energy‑efficient reactors
• Participation in national green chemistry certification programs

7. Qingdao Sigma Chemical Co., Ltd.

Headquarters: Qingdao, China
Key Offering: Pharmaceutical‑grade chiral amines, custom synthesis

Qingdao Sigma’s focus on process optimization allows it to meet the strict purity requirements of EU and US markets, making it a reliable partner for global CDMOs.

Sustainability/Growth Initiatives:

• Deployment of renewable electricity for production lines
• Development of a waste‑valorization program for by‑products
• Engagement with international quality‑assurance bodies

8. Oakwood Chemical

Headquarters: New York, USA
Key Offering: Rapid prototyping of chiral intermediates, small‑batch production

Oakwood’s agile manufacturing approach enables it to serve niche biotech projects that demand quick access to custom chiral amines.

Sustainability/Growth Initiatives:

• Integration of digital twins for process simulation
• Investment in green solvents for reductive amination
• Strategic alliances with US‑based CDMOs to expand reach

9. AstaTech, Inc.

Headquarters: San Francisco, USA
Key Offering: Research‑grade chiral amines, high‑throughput synthesis

AstaTech’s high‑throughput platforms support academic labs and early‑stage biotech firms, accelerating the discovery of new therapeutic candidates.

Sustainability/Growth Initiatives:

• Adoption of biocatalytic processes to reduce carbon footprint
• Implementation of circular economy principles in raw‑material sourcing
• Collaboration with venture capital to fund green‑innovation projects

10. Leancare Ltd.

Headquarters: Paris, France
Key Offering: Pharmaceutical‑grade chiral amines, GMP‑certified production

Leancare’s focus on stringent GMP compliance and quality control makes it a preferred supplier for European CDMOs and pharmaceutical manufacturers.

Sustainability/Growth Initiatives:

• Implementation of ISO 14001 environmental management systems
• Use of renewable energy sources across all facilities
• Participation in EU green chemistry initiatives

Download FREE Sample Report: (R)-N-Benzyl-1-phenyl ethylamine (CAS 38235-77-7) Market – View in Detailed Research Report

Get Full Report: (R)-N-Benzyl-1-phenyl ethylamine (CAS 38235-77-7) Market – View in Detailed Research Report

Outlook

Over the next decade, the market for (R)-N-Benzyl-1-phenyl ethylamine will continue to expand as pharmaceutical companies prioritize chiral purity to meet regulatory expectations and enhance therapeutic efficacy. The combination of advanced asymmetric catalysis, continuous‑flow synthesis, and biocatalytic routes will drive higher yields and lower production costs, reinforcing the compound’s position as a cornerstone of modern drug development.

Future Trends

• Integration of machine‑learning algorithms to predict optimal reaction conditions for chiral resolution
• Expansion of the compound’s role in peptide‑based therapeutics and conjugated drug platforms
• Greater emphasis on sustainability metrics, with suppliers pursuing carbon‑neutral operations and waste‑free manufacturing processes